Marina Konopleva

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 124 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer(2021)10.1002/cncr.33689

N/A

3.9DataRank · unranked

158 citations

Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch +14 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Clinical Infectious Diseases(2020)10.1093/cid/ciaa358

N/A

3.1DataRank · unranked

77 citations

David McCue, Sebastian Wurster, Nathan P. Wiederhold, Marina Konopleva, Tapan M. Kadia +18 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Blood Cancer Journal(2022)10.1038/s41408-021-00604-2

N/A

2.5DataRank · unranked

95 citations

Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi +14 more

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

Nature(2024)10.1038/s41586-024-08137-x

N/A

1.7DataRank · unranked

86 citations

Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour, Gulay Ulukaya +23 more

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26122

N/A

1.4DataRank · unranked

25 citations

Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia +11 more

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0029

N/A

1.4DataRank · unranked

34 citations

Tianyu Cai, Xia Li, Xiaoli Huang, Mai H. Bui, Joshua P. Plotnik +26 more

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood(2020)10.1182/blood.2019003988

N/A

0.969DataRank · unranked

638 citations

Ing Soo Tiong, Anna Quaglieri, Sarah MacRaild, Sanam Loghavi, Fiona C. Brown +24 more

Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study

American Journal of Hematology(2021)10.1002/ajh.26281

N/A

0.952DataRank · unranked

32 citations

Keyur P. Patel, Nitin Jain, Dzifa Y. Duose, Rajyalakshmi Luthra, Nicholas J. Short +8 more

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023012231

N/A

0.940DataRank · unranked

34 citations

Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi Haddad +18 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

Blood(2021)10.1182/blood.2020007748

N/A

0.848DataRank · unranked

284 citations

Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Ana Karen Nunez Cortes +56 more

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00250-3

N/A

0.561DataRank · unranked

17 citations

Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa +14 more

Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes

Frontiers in Oncology(2021)10.3389/fonc.2021.705627

N/A

0.557DataRank · unranked

12 citations

Vakul Mohanty, Ruiping Wang, Yuefan Huang, Shaoheng Liang, Feng Wang +13 more

A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.05.013

N/A

0.344DataRank · unranked

8 citations

Elias Jabbour, Nicholas J. Short, Tapan M. Kadia, Naveen Pemmaraju, Koichi Takahashi +4 more

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1973675

N/A

0.308DataRank · unranked

5 citations

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi +13 more

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.03.29.014472

N/A

0.224DataRank · unranked

2 citations

Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Ana Karen Nunez Cortes +55 more

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

Nature Cancer(2021)10.1038/s43018-020-00167-4

N/A

0DataRank · unranked

159 citations

Jingjing Liu, Jianzhong Hu, Wentao Yang, Neekesh V. Dharia, Jingliao Zhang +42 more

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Nature Communications(2021)10.1038/s41467-021-27210-x

N/A

0DataRank · unranked

149 citations

Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang +19 more

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Nature Communications(2021)10.1038/s41467-021-26282-z

N/A

0DataRank · unranked

132 citations

Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K. Reville +28 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature Communications(2021)10.1038/s41467-021-22874-x

N/A

0DataRank · unranked

117 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0DataRank · unranked

99 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis

Blood(2021)10.1182/blood.2021011247

N/A

0DataRank · unranked

58 citations

Xiaoping Xie, Zuliang Jie, Lele Zhu, Jin‐Young Yang, Chun‐Jung Ko +8 more

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26238

N/A

0DataRank · unranked

55 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Naval Daver, Tapan M. Kadia +8 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Blood Advances(2021)10.1182/bloodadvances.2020003934

N/A

0DataRank · unranked

48 citations

Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia +7 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood(2021)10.1182/blood.2020010483

N/A

0DataRank · unranked

43 citations

Kiyomi Morita, Sanam Loghavi, Feng Wang, Ken Furudate, Yuya Sasaki +19 more

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01106-1

N/A

0DataRank · unranked

37 citations

Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti +11 more

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

American Journal of Hematology(2021)10.1002/ajh.26417

N/A

0DataRank · unranked

37 citations

Marina Konopleva, Mrinal M. Patnaik, Elias Jabbour, Courtney D. DiNardo, Aref Al‐Kali +7 more

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia

Haematologica(2021)10.3324/haematol.2021.278369

N/A

0DataRank · unranked

32 citations

Huaxian Ma, Prerna Malaney, Xiaorui Zhang, Marisa J.L. Aitken, Po Yee Mak +12 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

Haematologica(2021)10.3324/haematol.2021.278697

N/A

0DataRank · unranked

25 citations

Joseph P. Loftus, Élodie Lainey, Aurélie Caye‐Eude, Morgane Pondrom, David A. Hottman +9 more

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2021)10.1038/s41467-021-23280-z

N/A

0DataRank · unranked

7 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Signal Transduction and Targeted Therapy(2022)10.1038/s41392-021-00870-3

N/A

0DataRank · unranked

186 citations

Bridget Riley‐Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang +36 more

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

Nature Communications(2022)10.1038/s41467-022-30396-3

N/A

0DataRank · unranked

63 citations

Alessia Lodi, Yogesh Dhungana, Shelley M. Herbrich, Meghan Collins, Shannon Sweeney +50 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Activated B cells suppress T-cell function through metabolic competition

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005644

N/A

0DataRank · unranked

36 citations

Rafet Başar, Yuefan Huang, Fang Wang, Natalia Baran, Pinaki P. Banerjee +22 more

Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia

Nature Communications(2022)10.1038/s41467-022-33143-w

N/A

0DataRank · unranked

27 citations

Ping Wang, Jonathan D. Diedrich, Brandon Smart, Noemi Reyes, Satoshi Yoshimura +15 more

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Nature Communications(2022)10.1038/s41467-022-29669-8

N/A

0DataRank · unranked

43 citations

Agnès Gouble, Kathryn L. Black, Anna Skwarska, Ammar S. Naqvi, Deanne Taylor +28 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy

Haematologica(2022)10.3324/haematol.2022.280884

N/A

0DataRank · unranked

28 citations

Guopan Yu, Hongying Zhang, Mahesh Basyal, Charlie Ly, Bin Yuan +10 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0DataRank · unranked

23 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic–Resistant AML and AML Stem Cells

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-21-0690

N/A

0DataRank · unranked

16 citations

Po Yee Mak, Wenjing Tao, Qi Zhang, Vivian Ruvolo, Vinitha M. Kuruvilla +10 more

SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway

Clinical Lymphoma Myeloma & Leukemia(2022)10.1016/j.clml.2022.04.001

N/A

0DataRank · unranked

13 citations

Bing Z. Carter, Michael Andreeff, Marina Konopleva, Abhishek Maiti

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Blood Advances(2022)10.1182/bloodadvances.2021006689

N/A

0DataRank · unranked

1 citations

Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short +6 more

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

Leukemia Research(2022)10.1016/j.leukres.2022.106884

N/A

0DataRank · unranked

1 citations

Alexandre Bazinet, Sanam Loghavi, Marina Konopleva, Kapil N. Bhalla, Naval Daver +10 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

Haematologica(2023)10.3324/haematol.2022.281915

N/A

0DataRank · unranked

68 citations

Lina Han, Cassandra L. Ramage, Zhe Wang, Connie C. Weng, Lei Yang +15 more

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Cancers(2023)10.3390/cancers15071983

N/A

0DataRank · unranked

33 citations

Amber Gibson, Jiasen He, David McCall, Michael Roth, César Núnêz +23 more

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

Frontiers in Oncology(2023)10.3389/fonc.2023.1161254

N/A

0DataRank · unranked

27 citations

Mary Ayres, Natalia Baran, Janice M. Santiago‐O’Farrill, Gamze Bildik, Zhen Lü +3 more

Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Molecular Cancer Research(2023)10.1158/1541-7786.mcr-22-0343

N/A

0DataRank · unranked

16 citations

Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran +10 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances(2023)10.1182/bloodadvances.2022009632

N/A

0DataRank · unranked

24 citations

Faustine Ong, Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver +15 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro

Biochemical Pharmacology(2023)10.1016/j.bcp.2023.115981

N/A

0DataRank · unranked

18 citations

Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jianlei Zhao, Brianna R. Temby +24 more

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Blood Advances(2023)10.1182/bloodadvances.2022007728

N/A

0DataRank · unranked

14 citations

Karanpreet Singh Bhatia, Aarthi N. Mahesh, Shazwina Rosli, Jameelah S. Mohamed, Wei‐Ying Jen +8 more

Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia

Leukemia(2023)10.1038/s41375-023-01900-5

N/A

0DataRank · unranked

11 citations

John C. Panetta, Jianzhong Hu, Lie Li, Yoshihiro Gocho, Guoqing Du +10 more

Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Leukemia(2023)10.1038/s41375-023-02010-y

N/A

0DataRank · unranked

10 citations

Chunhua Shi, Guojun Yang, Jason Allen, Qing Shi, Amin Al-Shami +15 more

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

Frontiers in Immunology(2023)10.3389/fimmu.2023.1249511

N/A

0DataRank · unranked

9 citations

Naval Daver, Myrna C. B. Godoy, Girish S. Shroff, Carol C. Wu, Luis F. Torre-Sada +19 more

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Blood Advances(2023)10.1182/bloodadvances.2023010111

N/A

0DataRank · unranked

2 citations

Huaxian Ma, Mansour Alfayez, Daniel E. Morales-Mantilla, Fei Wang, Yue Lu +10 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and purine biosynthesis

Research Square(2023)10.21203/rs.3.rs-2843025/v1

N/A

0DataRank · unranked

2 citations

Katie Hege-Hurrish, Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jenna L. Carter +22 more

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.22.529457

N/A

0DataRank · unranked

1 citations

Feiyang Ma, Pamela Lockyer, Natalia Baran, Jintan Liu, C. Ellen Jackson +27 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood(2023)10.1182/blood-2023-181031

N/A

0DataRank · unranked

1 citations

Hina Khan, Denái R. Milton, Oren Pasvolsky, Mark R. Tanner, Uday Popat +18 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

medRxiv(2023)10.1101/2023.12.06.23299616

N/A

0DataRank · unranked

1 citations

Nicholas J. Short, Hagop M. Kantarjian, Ti‐Cheng Chang, Pankaj S. Ghate, Chunxu Qu +17 more

Data from Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim

(2023)10.1158/0008-5472.c.6500051.v1

N/A

0DataRank · unranked

0 citations

Marina Konopleva, Jared K. Burks, Karen C. Dywer, Wendy Schober, Jer‐Yen Yang +4 more

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Nature Communications(2024)10.1038/s41467-024-45916-6

N/A

0DataRank · unranked

66 citations

Patrick K. Reville, Mhd Yousuf Yassouf, Fatima Zahra Jelloul, Christopher Ly, Poonam N. Desai +27 more

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

Cancer Cell(2024)10.1016/j.ccell.2024.03.003

N/A

0DataRank · unranked

35 citations

Yizhen Li, Jingliao Zhang, Lei Yan, Huanbin Zhao, Liang Ding +21 more

Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile

Blood Advances(2024)10.1182/bloodadvances.2023011858

N/A

0DataRank · unranked

27 citations

Annelies Roobrouck, Geert Deschamps, Hélène Bonnevaux, S. Guérif, Veronique De Brabandere +7 more

Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia

Journal of Clinical Oncology(2024)10.1200/jco.24.00500

N/A

0DataRank · unranked

17 citations

Zhenhua Li, Yoshihiro Gocho, Wenjian Yang, Kristine R. Crews, Shawn H.R. Lee +21 more

Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models

Blood Advances(2024)10.1182/bloodadvances.2024013423

N/A

0DataRank · unranked

9 citations

Yizhen Li, Natalia Baran, Yang Xu, Sanaz Ghotbaldini, Qi Zhang Tatarata +11 more

BCL-2 inhibition in acute myeloid leukemia: resistance and combinations

Expert Review of Hematology(2024)10.1080/17474086.2024.2429604

N/A

0DataRank · unranked

8 citations

Zhe Wang, Marina Konopleva, Qi Zhang

Feasible diet and circadian interventions reduce in vivo progression of FLT3‐ITD‐positive acute myeloid leukemia

Cancer Medicine(2024)10.1002/cam4.6949

N/A

0DataRank · unranked

5 citations

Baharan Fekry, Brianna R. Murphy, Mary Figueroa, Tiewei Cheng, Margaret Raber +15 more

Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia

Current Pharmacology Reports(2024)10.1007/s40495-024-00378-8

N/A

0DataRank · unranked

3 citations

Monika Chomczyk, Shubhankar Dash, Marina Konopleva, Natalia Baran, Patryk Firmanty

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.01.27.577579

N/A

0DataRank · unranked

10 citations

Natalia Baran, Yuefan Huang, Cassandra L. Ramage, Laurie Cooper, Shan He +7 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

BH3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism

Research Square(2024)10.21203/rs.3.rs-5307127/v1

N/A

0DataRank · unranked

0 citations

Kapil Saxena, Esther Ryu, Shao-Hsi Hung, Shailbala Singh, Qi Zhang +4 more

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts

Blood Advances(2025)10.1182/bloodadvances.2024015441

N/A

0DataRank · unranked

31 citations

Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica Leonard, Aaron C. Logan +5 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

Nature Reviews Clinical Oncology(2025)10.1038/s41571-025-01068-0

N/A

0DataRank · unranked

12 citations

Ellen Weisberg, Hiu Yan Lam, Donavan J. J. Tan, Andrew J. Innes, Yubin Ge +17 more

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Blood(2025)10.1182/blood.2025028985

N/A

0DataRank · unranked

7 citations

Ilaria Iacobucci, Qingsong Gao, Jamila Moore, William C. Wright, Huimei Wei +20 more

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin

Blood(2025)10.1182/blood.2024028215

N/A

0DataRank · unranked

7 citations

Zhenhua Li, Kelly R. Barnett, Yizhen Li, Megan Walker, Satoshi Yoshimura +16 more

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Blood Neoplasia(2025)10.1016/j.bneo.2025.100121

N/A

0DataRank · unranked

3 citations

Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Zhihong Zeng +10 more

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016565

N/A

0DataRank · unranked

3 citations

Hagop M. Kantarjian, Nitin B. Jain, Tapan M. Kadia, Jayastu Senapati, Fadi Haddad +12 more

First‐line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial

British Journal of Haematology(2025)10.1111/bjh.70209

N/A

0DataRank · unranked

2 citations

Andrew A. Lane, Kendra Sweet, Sumithira Vasu, Alessandra Tosolini, John Katsetos +3 more

BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism

Cell Death Discovery(2025)10.1038/s41420-025-02375-2

N/A

0DataRank · unranked

7 citations

Shao-Hsi Hung, Esther Ryu, Shailbala Singh, Qi Zhang Tatarata, Zhihong Zeng +4 more

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica(2025)10.3324/haematol.2025.288553

N/A

0DataRank · unranked

2 citations

Sanam Loghavi, Musa Yılmaz, Omer Karrar, Kunhwa Kim, Courtney D. DiNardo +15 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

Quiescent OXPHOS-High Triple-Negative Breast Cancer Cells That Persist After Chemotherapy Depend on BCL-XL for Survival

Cells(2025)10.3390/cells14191557

N/A

0DataRank · unranked

1 citations

Marie Winter, Leandro Encarnação Garcia, Olusiji Akinrinmade, Francisco Madeira Marques, Emmanouil Zacharioudakis +10 more

The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.07.03.662851

N/A

0DataRank · unranked

2 citations

Wai-Kin Chan, Lin Tan, Alvina I. Khamidullina, Iqbal Mahmud, Shwetha V. Kumar +12 more

Quiescent OXPHOS-high triple-negative breast cancer cells that persist after chemotherapy depend on BCL-XL for survival

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.08.21.671546

N/A

0DataRank · unranked

2 citations

Marie Winter, Leandro Encarnacao. Garcia, Olusiji Akinrinmade, Francisco Madeira Marques, Emmanouil Zacharioudakis +10 more

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.10.27.684888

N/A

0DataRank · unranked

1 citations

Dennis Juarez, Madhuri Paul, Sarah J. Skuli, Ian B. Wong, Ian Y. Wong +12 more

Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.64898/2025.12.16.693978

N/A

0DataRank · unranked

1 citations

Marta Obacz, Jerzy Woźnicki, Katarzyna Wiklik, Samarpana Chakraborty, Marta Micek +17 more

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program

Discover Oncology(2025)10.1007/s12672-025-02433-2

N/A

0DataRank · unranked

0 citations

Maria Badikyan, Marina Konopleva, Alvaro J. Alencar, Arusyak Ivanyan, Carolyn Owen +34 more

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2020003120

N/A

0DataRank · unranked

182 citations

Guillermo Montalban‐Bravo, Hyunsoo Hwang, Jing Ning, Miguel Franquiz, Rashmi Kanagal‐Shamanna +12 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2020)10.1038/s41467-020-19119-8

N/A

0DataRank · unranked

391 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Blood Advances(2020)10.1182/bloodadvances.2019000173

N/A

0DataRank · unranked

68 citations

Marina Konopleva, Naveen Pemmaraju

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model

Frontiers in Oncology(2020)10.3389/fonc.2020.00991

N/A

0DataRank · unranked

18 citations

Karine G. Harutyunyan, Natalia Baran, Saradhi Mallampati, Malgorzata Anna Zal, Antonio Cavazos +9 more

Utilizing Synergistic Potential of Mitochondria-Targeting Drugs for Leukemia Therapy

Frontiers in Oncology(2020)10.3389/fonc.2020.00435

N/A

0DataRank · unranked

41 citations

Jingqi Pei, Natalia Baran, Marina Konopleva, Natalia V. Kirienko, Svetlana Panina

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Blood Cancer Journal(2020)10.1038/s41408-020-0329-y

N/A

0DataRank · unranked

36 citations

Hagop M. Kantarjian, Rashmi Kanagal‐Shamanna, Koji Sasaki, Farhad Ravandi, Jörge E. Cortes +15 more

Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway

PLoS ONE(2020)10.1371/journal.pone.0242809

N/A

0DataRank · unranked

36 citations

Fouad El Dana, Stanley Ly, Yuanqing Yan, Vivian Ruvolo, Elizabeth J. Shpall +4 more

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more

Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.02.07.925743

N/A

0DataRank · unranked

67 citations

Feng Wang, Katharina Jahn, Jack Kuipers, Yuanqing Yan, Jairo Matthews +22 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.27.357111

N/A

0DataRank · unranked

20 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Bone marrow stromal cells induce an ALDH + stem cell-like phenotype in AML cells through TGF-β-p38-ALDH2 pathway

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.07.10.197178

N/A

0DataRank · unranked

4 citations

Fouad El Dana, Stanley Ly, Yuanqing Yan, Vivian Ruvolo, Elizabeth J. Shpall +4 more

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.03.278309

N/A

0DataRank · unranked

3 citations

Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K. Reville +22 more

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood(2021)10.1182/blood.2021013626

N/A

0DataRank · unranked

738 citations

Sylvie Freeman, Gert J. Ossenkoppele, Francesco Buccisano, Christopher S. Hourigan, Lok Lam Ngai +40 more